BioInvent Q2 FY26 net loss widens to SEK 122.9 million; net sales fall to SEK 12.8 million

• BioInvent posted a Q2 net loss of SEK 122.9 million, swinging from a profit a year earlier; net sales fell to SEK 12.8 million.
• Operating cash flow worsened to SEK -112 million; cash and short-term investments ended at SEK 340.8 million.
• H1 net loss widened to SEK 242.1 million; net sales dropped to SEK 26.2 million, due mainly to a EUR 1 million milestone payment.
• BI-1808 with Keytruda delivered a 24% confirmed ORR in advanced ovarian cancer (n=25); FDA granted Fast Track for ovarian cancer.
• Management said the group is funded into late Q1 2027; it is evaluating financing options with plans to address funding in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioInvent International AB published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.